[Experimental study on antitumor effect of cisplatin-microcapsule]

Area of Science:

• Oncology
• Materials Science
• Pharmacology

Context:

• Developing novel drug delivery systems for chemotherapy is crucial for improving treatment efficacy and patient outcomes.
• Conventional cisplatin administration can lead to significant systemic toxicity.
• Microencapsulation offers a potential strategy to control drug release and target tumor sites.

Purpose:

• To evaluate the properties, biological effects, and antitumor activity of cisplatin-loaded microcapsules (CDDP-mc).
• To assess the feasibility of using CDDP-mc as a targeted drug delivery system for cancer treatment.
• To compare the efficacy and side effects of CDDP-mc with conventional cisplatin solutions.

Summary:

• Cisplatin microcapsules (CDDP-mc) demonstrated a sustained release of cisplatin over 48 hours in saline.
• The microcapsules, sized 80-200 microns, contain a high concentration of cisplatin, enabling targeted delivery to tumor tissues.
• CDDP-mc exhibited reduced side effects in animal models compared to standard cisplatin, particularly with intraperitoneal and local injections.
• Intraperitoneal administration of CDDP-mc showed superior efficacy against Yoshida's sarcoma in rats compared to conventional cisplatin.
• Subcutaneous administration of CDDP-mc was also more effective than the standard solution.
• Intraarterial infusion of CDDP-mc resulted in temporary limb palsy, likely due to embolism.

Impact:

• CDDP-mc shows significant potential for clinical application in treating ovarian and uterine cancers via intraperitoneal and local intra-tumor administration.
• The microencapsulation technology provides a viable approach for enhancing the therapeutic index of cisplatin.
• Further research into optimizing administration routes and mitigating potential embolism risks is warranted.